DEA Greenlights Opium Imports for Siegfried USA—Legal Highs Ahead?
Published Date: 1/22/2026
Notice
Summary
Siegfried USA, LLC wants to become an official importer of certain controlled substances, like phenylacetone and raw opium. This affects companies handling these drugs and anyone interested can comment or request a hearing by February 23, 2026. No direct costs are mentioned, but this move could impact drug supply chains and regulations.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Comment and Hearing Deadline
Registered bulk manufacturers and applicants can submit electronic comments or objections about Siegfried USA, LLC's importer application, or file a written request for a hearing, on or before February 23, 2026. Comments must be submitted through https://www.regulations.gov and hearing requests must be sent to the DEA addresses listed in the notice.
Importer Application for Schedule II APIs
Siegfried USA, LLC applied on November 27, 2025 to be registered to import the Schedule II substances phenylacetone (code 8501), opium, raw (code 9600), and poppy straw concentrate (code 9670). The company states it plans to import these substances only to manufacture bulk active pharmaceutical ingredients for distribution to its customers, and the registration will not authorize import of finished dosage forms for commercial sale.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-01193 — L-Lysine From the People's Republic of China: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Determination With Final Antidumping Duty Determination
The U.S. government found that Chinese companies making L-lysine, a common animal feed ingredient, are getting unfair financial help from their government. Because of this, the U.S. plans to add extra taxes (countervailing duties) on these imports to keep things fair for American businesses. This decision starts January 22, 2026, and could affect prices and trade between the U.S. and China.
Next: 2026-01195 — Notice of Intent To Extend and Revise a Previously Approved Information Collection
The USDA’s National Institute of Food and Agriculture plans to extend and update the Expanded Food and Nutrition Education Program’s data collection for three more years. This affects educators and volunteers teaching nutrition to families with limited money across all 50 states and territories. They’re asking for public comments by March 23, 2026, to help improve how they track and boost the program’s impact.